Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01677962 · ClinicalTrials.gov registry record · Phase 1
A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma
A Phase 1 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01677962 is a Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 12 participants.
The verdict
NCT01677962, a Phase 1 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The main purpose of this study is to examine the safety of the study drug in patients with locally advanced unresectable pancreatic adenocarcinoma. The study team would like to know about any side effects a patient may have when given the study drug. Another goal of the study is to determine if combining dendritic cells and the study drug can be possibly used as a vaccine for this disease. Dendritic cells are cells that are present in the body's immune system that help your body fight disease.
Interventions
- BIOLOGICAL Poly-ICLC
- BIOLOGICAL dendritic cell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-08 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01677962
The ClinicalTrials.gov registry entry for NCT01677962 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Poly-ICLC is the first listed.
NCT01677962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01677962 about?
NCT01677962 is a clinical study titled "A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma". The main purpose of this study is to examine the safety of the study drug in patients with locally advanced unresectable pancreatic adenocarcinoma. The study team would like to know about any side effects a patient may have when given the study drug. Another goal of the study is to determine if comb...
What is the current status of trial NCT01677962?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-08. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01677962?
The interventions under investigation include: Poly-ICLC (BIOLOGICAL), dendritic cell (BIOLOGICAL).
Who is sponsoring clinical trial NCT01677962?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.